Core Viewpoint - An amended securities class action lawsuit has been filed against CarMax, Inc., expanding the class period to include purchases made between June 20, 2025, and November 5, 2025, with a lead plaintiff deadline set for January 2, 2026 [1]. Group 1: Allegations Against CarMax - The complaint alleges that CarMax's defendants made false and misleading statements regarding the company's growth prospects, claiming that the earlier growth in the 2026 fiscal year was merely a temporary benefit due to customer speculation about tariffs [2]. - It is asserted that the positive statements made by the defendants about CarMax's business and operations were materially misleading and lacked a reasonable basis throughout the class period [2]. Group 2: Lead Plaintiff Process - Investors in CarMax have until January 2, 2026, to seek appointment as a lead plaintiff representative of the class, or they may choose to remain absent class members [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the proposed class [3]. Group 3: Law Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of fraud and corporate misconduct [4].

Company Overview - Soleno Therapeutics, Inc. (NASDAQ: SLNO) is under investigation for potential violations of U.S. federal securities laws, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1][2]. Recent Developments - On March 26, 2025, Soleno announced FDA approval for VYKAT XR (diazoxide choline) extended-release tablets, intended for treating hyperphagia in individuals with Prader-Willi syndrome aged 4 and older [3]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for VYKAT XR due to adverse effects by the end of Q3 2025. The CEO acknowledged a disruption in the product's launch trajectory following a short seller report released in mid-August, which led to a decrease in start forms and an increase in discontinuations for non-serious adverse events [4]. Market Reaction - Following the earnings call and the revelation of the discontinuation rate, Soleno's share price experienced a decline of over 26% [4].

Nov 7, 2025 5:01 PM Eastern Standard Time Deadline Soon: Lantheus Holdings, Inc. (LNTH) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit Share LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 10, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Lantheus Holdings, Inc. ("Lantheus†or the "Company†) (NASDAQ: ...

Core Points - James Hardie Industries plc is facing a class action lawsuit due to a significant decline in sales, specifically a 12% drop in North America Fiber Cement sales attributed to customer destocking [2][4] - The company's stock price plummeted by $9.79, or 34.4%, closing at $18.64 per share following the announcement of the sales decline [3] - The lawsuit alleges that the company made materially false and misleading statements regarding its business operations and failed to disclose adverse facts about its sales performance [4] Company Summary - James Hardie Industries plc's common stock was previously American Depositary Shares until its conversion on July 1, 2025 [1] - The class period for the lawsuit is defined as May 20, 2025, to August 18, 2025 [1][5] - Investors who purchased shares during this period are encouraged to file a lead plaintiff motion by December 23, 2025 [5]

Core Viewpoint - V.F. Corporation is facing a class action securities lawsuit due to alleged securities fraud that affected investors between October 30, 2023, and May 20, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that V.F. Corporation made materially false and misleading statements regarding its turnaround plans, particularly concerning the Vans brand, which required additional significant reset actions to return to growth [2]. - Following the release of V.F. Corporation's fiscal 2025 results on May 21, 2025, it was revealed that Vans experienced a decline in growth, with losses worsening from 8% to 20% in the fourth quarter [2]. - The company's guidance indicated that even without the deliberate actions taken, Vans would still show a "high single digit" revenue decline, suggesting a slowdown in growth compared to previous years [2]. Group 2: Stock Price Impact - On May 20, 2025, V.F. Corporation's stock closed at $14.43 per share, but following the negative news, it dropped to $12.15 per share on May 21, 2025, marking a decline of approximately 15.8% in one day [2]. Group 3: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 12, 2025, to request to be appointed as lead plaintiff in the class action lawsuit [3]. - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [3]. Group 4: Law Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - It is alleged that the supposed increased tissue penetration of SLK would not lead to improved clinical efficacy, indicating that the defendants lacked a reasonable basis for their positive claims about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, emphasizing that there is no financial obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Fortinet, Inc. for alleged securities fraud affecting investors between November 8, 2024, and August 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Fortinet's management made false statements regarding the refresh cycle of their products, suggesting it would be more profitable than it actually was, as it involved old products that represented a "small percentage" of the company's business [2]. - It is alleged that Fortinet misrepresented the number of FortiGate firewalls eligible for upgrades and that the company had pushed through approximately half of the refresh in just a few months, contrary to claims of a two-year momentum [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between November 7, 2024, and September 12, 2025 [1][2] - The lawsuit claims that aTyr made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant stock price drop of 83.2% from $6.03 to $1.02 per share [2] Case Details - The lawsuit seeks to recover losses for investors who were misled by the company's positive statements while concealing adverse facts about the drug's efficacy [2] - Following the announcement of disappointing study results, aTyr plans to engage with the FDA to determine the next steps [2] Next Steps for Investors - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Participation in the class action does not require serving as a lead plaintiff, and there are no costs or obligations for class members [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud related to the company's glucose monitoring products, specifically the G6 and G7 models, which are claimed to have undergone unauthorized design changes that compromised their reliability and safety [1][2]. Group 1: Allegations and Impact - The lawsuit claims that DexCom made material design changes to the G6 and G7 glucose monitoring products without FDA authorization [2]. - These design changes allegedly rendered the devices less reliable, posing a material health risk to users who depend on them for accurate glucose readings [2]. - The enhancements claimed by the defendants regarding the G7's reliability, accuracy, and functionality were reportedly overstated [2]. - The lawsuit suggests that the company downplayed the severity of the issues and health risks associated with the altered G7 devices [2]. - As a result of these actions, DexCom is said to face increased regulatory scrutiny and potential legal, reputational, and financial harm [2]. - The public statements made by the defendants are characterized as materially false and misleading throughout the relevant time period [2]. Group 2: Legal Process and Participation - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require individuals to serve as lead plaintiffs, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant recoveries for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Accessibility StatementSkip Navigation NEW YORK, Nov. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https:/ ...